Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Xenetic Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -75.9%. For fiscal 2025 it was -90.1%, against -158.4% the year before. The highest annual figure on record is -47.4% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -90.1% | +68.3 |
| FY2024 | Dec 31, 2024 | -158.4% | +4.4 |
| FY2023 | Dec 31, 2023 | -162.8% | +221.1 |
| FY2022 | Dec 31, 2022 | -383.9% | +102.5 |
| FY2021 | Dec 31, 2021 | -486.4% | +2006.8 |
| FY2020 | Dec 31, 2020 | -2493.1% | +72363.5 |
| FY2019 | Dec 31, 2019 | -74856.6% | −74809.2 |
| FY2017 | Dec 31, 2017 | -47.4% | +1759.5 |
| FY2016 | Dec 31, 2016 | -1806.9% | −948.9 |
| FY2013 | Dec 31, 2013 | -857.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -140.7% | −24.0 |
| Q1 FY2026 | Mar 31, 2026 | -56.6% | +95.7 |
| Q4 FY2025 | Dec 31, 2025 | -75.6% | +87.0 |
| Q3 FY2025 | Sep 30, 2025 | -49.7% | +21.4 |
| Q2 FY2025 | Jun 30, 2025 | -116.7% | +58.6 |
| Q1 FY2025 | Mar 31, 2025 | -152.2% | +81.7 |
| Q4 FY2024 | Dec 31, 2024 | -162.5% | +11.8 |
| Q3 FY2024 | Sep 30, 2024 | -71.1% | +101.6 |
| Q2 FY2024 | Jun 30, 2024 | -175.4% | −13.9 |
| Q1 FY2024 | Mar 31, 2024 | -234.0% | −92.6 |
| Q4 FY2023 | Dec 31, 2023 | -174.3% | +466.9 |
| Q3 FY2023 | Sep 30, 2023 | -172.7% | +237.0 |
| Q2 FY2023 | Jun 30, 2023 | -161.4% | +392.3 |
| Q1 FY2023 | Mar 31, 2023 | -141.4% | +245.4 |
| Q2 FY2022 | Jun 30, 2022 | -641.3% | −256.5 |
| Q1 FY2022 | Mar 31, 2022 | -409.7% | +294.2 |
| Q4 FY2021 | Dec 31, 2021 | -553.7% | +239.3 |
| Q3 FY2021 | Sep 30, 2021 | -386.8% | +6134.5 |
| Q2 FY2021 | Jun 30, 2021 | -384.8% | +459.7 |
| Q1 FY2021 | Mar 31, 2021 | -703.9% | +1374.4 |
| Q4 FY2020 | Dec 31, 2020 | -793.0% | +6064.2 |
| Q3 FY2020 | Sep 30, 2020 | -6521.3% | −6580.5 |
| Q2 FY2020 | Jun 30, 2020 | -844.5% | +1809.5 |
| Q1 FY2020 | Mar 31, 2020 | -2078.3% | −2065.3 |
| Q4 FY2019 | Dec 31, 2019 | -6857.2% | – |
| Q4 FY2017 | Dec 31, 2017 | 59.3% | – |
| Q3 FY2017 | Sep 30, 2017 | -2654.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -13.0% | – |
See a number that looks wrong?